Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
- To demonstrate the superiority of CHF 5993 100/6/12.5 pMDI compared to CHF 1535 100/6 pMDI in terms of change from baseline in pre-dose FEV1 at Week 26. - To demonstrate the reduction of moderate and severe asthma exacerbations rate with CHF 5993 100/6/12.5 pMDI compared to CHF 1535 100/6 pMDI during the entire 52-week treatment period.
Critère d'inclusion
- uncontrolled asthma